(P1) German biopharmaceutical firm InflaRx N.V. (IFRX) completed its previously announced underwritten public offering of 75 million ordinary shares, raising $150 million in gross proceeds before underwriting discounts and expenses.
(P2) "The financing included participation from new and existing investors, including TCGX, a large healthcare-dedicated fund, Farallon Capital Management, and others," the company said in a press release.
(P3) The offering was priced at $2.00 per share, a noticeable discount to its closing price of $2.65 on the day of the announcement. The transaction increases the company's total shares outstanding, resulting in dilution for current investors. The net proceeds are intended for advancing the company's pipeline activities, working capital, and general corporate purposes.
(P4) The capital raise is a critical step for InflaRx as it develops its lead drug candidate, izicopan. For existing investors, the lower offering price presents a potential opportunity to average down their cost basis, a strategy where more shares are purchased at a lower price to reduce the average cost per share.
The $150 million capital injection provides InflaRx with a significant cash runway to fund its clinical trials and research endeavors. The company's lead program, izicopan, is an orally administered inhibitor of the C5a receptor, being developed for AAV and other renal diseases.
However, the offering at $2.00 per share, while the stock was trading higher, has a dilutive effect on existing share ownership. This means each existing share now represents a smaller percentage of the company. Such offerings are common for development-stage biotech companies that are not yet profitable and require substantial capital for research and development. The success of the investment will hinge on the company’s ability to use the funds to successfully bring its products to market.
The offering was managed by a syndicate of banks, with Guggenheim Securities acting as the lead bookrunner.
This article is for informational purposes only and does not constitute investment advice.
